Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
出版年份 2019 全文链接
标题
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 19, Pages 4931
出版商
MDPI AG
发表日期
2019-10-07
DOI
10.3390/ijms20194931
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
- (2019) Andrea Bianco et al. Translational Cancer Research
- Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
- (2019) Alfonso Fiorelli et al. Journal of Cardiothoracic Surgery
- Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
- (2019) Fabio Perrotta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC.
- (2019) Melinda D Willard et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
- (2019) Ferdinandos Skoulidis et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
- (2019) Michael Friedrich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
- (2018) Tricia R. Cottrell et al. CANCER JOURNAL
- Targeting immune checkpoints in non small cell lung cancer
- (2018) Andrea Bianco et al. CURRENT OPINION IN PHARMACOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- (2018) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
- (2018) Anton Uryvaev et al. MEDICAL ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Oncogene-addicted non-small cell lung cancer and immunotherapy
- (2018) Georgios Tsakonas et al. Journal of Thoracic Disease
- The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
- (2018) Lilla Hornyák et al. Frontiers in Immunology
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients
- (2018) Ryo Kato et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
- (2018) Prabhakaran Kumar et al. JOURNAL OF AUTOIMMUNITY
- High-dimensional single cell analysis identifies stem-like cytotoxic CD8+T cells infiltrating human tumors
- (2018) Jolanda Brummelman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
- (2018) Andrea Botticelli et al. Journal of Translational Medicine
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Lung Cancer
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
- (2018) Yosuke Miura et al. Cancers
- Contribution of regulatory T cells to cancer: A review
- (2018) Masoud Najafi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- T lymphocyte subsets in cancer immunity: Friends or foes
- (2018) Dounia Chraa et al. JOURNAL OF LEUKOCYTE BIOLOGY
- TIM-3, a promising target for cancer immunotherapy
- (2018) Yayi He et al. OncoTargets and Therapy
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
- (2017) Francesco Facchinetti et al. LUNG CANCER
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
- (2017) Zhixin Sheng et al. Oncotarget
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
- (2017) Liting Guo et al. Journal of Cancer
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- (2017) Hyun Tae Lee et al. Scientific Reports
- Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM)
- (2016) D. Planchard et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
- (2016) Joohee Sul et al. ONCOLOGIST
- Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer
- (2015) Joseph D. Phillips et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
- (2015) Fayçal Djenidi et al. JOURNAL OF IMMUNOLOGY
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
- (2015) Kurt A. Schalper et al. JNCI-Journal of the National Cancer Institute
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
- (2015) Nicolas Pécuchet et al. Oncotarget
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
- (2015) Kurt A. Schalper et al. JNCI-Journal of the National Cancer Institute
- Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma
- (2015) G-Andre Banat et al. PLoS One
- Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2014) S. Gettinger et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
- (2012) S Liu et al. CELL DEATH AND DIFFERENTIATION
- Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
- (2010) N. Jain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD4+regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
- (2009) Randall H. Friedline et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now